title: A novel topical rapamycin cream for the treatment of facial angiofibromas in tuberous sclerosis complex.
abstract: Facial angiofibromas are dermatological manifestations of tuberous sclerosis complex, a neurocutaneous disorder characterized by excess cell growth and proliferation. Oral rapamycin has been used to treat visceral tuberous sclerosis-related tumors; however, the side effect profile of this medicine precludes its routine use in patients lacking significant internal involvement. The authors formulated a novel rapamycin cream that is easy to compound and apply, does not cause local or systemic side effects, and results in a dramatic improvement of facial angiofibromas.
authors.affiliation: Division of Pediatric Neurology, Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN 38105, USA. jwheless@uthsc.edu
authors.forename: James W
authors.initials: JW
authors.lastname: Wheless
authors.forename: Hassan
authors.initials: H
authors.lastname: Almoazen
mesh_terms: D018322:Angiofibroma / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D002648:Child; D005153:Facial Neoplasms / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D020123:Sirolimus / Q000008:administration & dosage*; D063465:Skin Cream / Q000008:administration & dosage; D013997:Time Factors; D014402:Tuberous Sclerosis / Q000150:complications
chemical_list: D000903:Antibiotics, Antineoplastic; D020123:Sirolimus
keywords: facial angiofibroma; rapamycin; treatment; tuberous sclerosis complex